A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find the highest dose level of study drug, CTT1403, that can
be safely administered to patients with metastatic castration resistant prostate cancer
(mCRPC).